In 27 of the 29 states where Ambetter sells plans, every state except California and New York, Ambetter will not pay for Wegovy, Zepbound or Foundayo (Lilly's daily GLP-1 pill) to help you lose weight.1, 2, 3 None of the three is on those states' 2026 drug lists, and the 2026 contracts we read exclude weight-loss drugs the list leaves out.1, 4, 5, 6 Centene, the company behind Ambetter, also calls weight-loss use of Wegovy and Zepbound "a benefit exclusion."7, 8
Ozempic and Mounjaro are on the standard lists, but Centene approves them for type 2 diabetes, not for weight loss or prediabetes.1, 9 The weight-loss drugs those lists do include are two older generic pills, phentermine and phendimetrazine, each needing prior authorization: your prescriber must get Ambetter's approval first. New York's list has phentermine, Contrave and phentermine-topiramate, but not phendimetrazine.1, 10
The other two states differ. Most of California's Ambetter plans cover weight-loss drugs under strict rules.11 New York's list leaves out Wegovy, Zepbound and Foundayo too, but its contract allows an exception request, and we found nothing showing how a weight-loss request would be decided there.10, 12 In the 27 standard-list states, Centene allows Zepbound for sleep apnea and Wegovy for cardiovascular disease or a serious liver disease, for people whose records already show those conditions.7, 8
Further down: the sleep apnea, heart and liver routes, California and New York, type 2 diabetes, how to check your own plan, what you can ask for after a no and paying without insurance.
Drug by drug on Ambetter's 2026 lists
Ambetter is Centene's brand of Marketplace health plans for individuals and families, sold in 29 states.3 Twenty-seven of those states use Centene's standard drug list (a drug list is also called a formulary). California's plans, run by Health Net, and New York's, run by Fidelis Care, publish their own. We searched all of the 2026 lists, 31 files in all, for each drug below.1, 10, 11
October 3, 2026: what Ambetter's 2026 drug lists show
| Drug |
Standard list (27 states) |
California |
| Ozempic (pen or tablets) |
Tier 2, PA |
Tier 2, PA |
| Mounjaro |
Tier 2, PA |
Tier 2, PA |
| Wegovy (pen or tablets) |
Not listed |
Most plans, PA* |
| Zepbound |
Not listed |
Most plans, PA* |
| Foundayo |
Not listed |
Most plans, PA* |
| Phentermine |
Low-copay tier, PA |
Most plans, PA* |
| Phendimetrazine |
Low-copay tier, PA |
Not listed |
PA means prior authorization. On the standard lists, tier 2 is the medium-copay tier for brand-name drugs; California's tier 2 holds preferred brand-name drugs and some generics. *After six months in a weight-loss program, and only if you meet your plan's BMI requirement.1, 11
California's rules and New York's list come later. Before choosing any of these drugs, read the warnings further down.
On the standard list, the Ozempic, Mounjaro, Rybelsus and Trulicity entries say "Smart PA," a code no Ambetter document we found defines, so expect your prescriber to file a request as usual.1 Generic liraglutide, the type 2 diabetes drug sold as Victoza, sits on a low-copay tier, and its row shows only a quantity limit. Centene's GLP-1 policy still lists liraglutide among the drugs that need prior authorization, so ask your pharmacist whether a request is needed.1, 9 Saxenda, the liraglutide brand approved for weight loss, is not on the standard lists.1
A listing is not a promise: the lists warn that a plan's design may still exclude a listed drug.1 The 2027 lists posted by October 3, 2026, for 25 of the 27 states, show the same pattern. New Hampshire's and Delaware's pharmacy pages still showed only their 2026 and 2025 lists.13, 14, 15
Why most Ambetter plans won't pay for weight-loss GLP-1s
Wegovy, Zepbound and Foundayo are FDA-approved, along with a reduced-calorie diet and more exercise, for long-term weight reduction in adults who have obesity, or overweight plus at least one weight-related health problem. The Wegovy injection is also approved for obesity from age 12.2, 16, 17 In the 27 standard-list states, Ambetter's documents close this route in three places:
-
The drug list. All three are missing from the 2026 lists, and the contracts treat a drug that is not listed as non-formulary, covered only through an exception.1, 4
-
The contract. The 2026 Evidence of Coverage we read for each of the 27 states pays nothing for weight-loss prescription drugs the formulary does not list. In 25 states it says what Georgia's says: "for weight loss prescription drugs unless otherwise listed on the formulary." Arizona's says the same in other words, and New Jersey's standard individual policy goes further and excludes drugs used solely for weight loss.4, 5, 6
-
Centene's drug policies. Its Wegovy and Zepbound policies for Ambetter plans, both reviewed in September 2026, say that use for weight management "is a benefit exclusion and will not be authorized."7, 8
The usual fallback is an exception request for a drug that is not on the list. Centene's rules say those will not be approved for weight loss: a request must not be "for a benefit excluded use," and the rules give "non-formulary weight loss drugs" as an example. Arizona's contract offers exceptions only for drugs "not specifically excluded from coverage."5, 18 You can still ask, appeal and seek an outside review; what that can change is below.
Federal rules set only a floor. A Marketplace plan must cover at least one drug in every drug class, or as many as the state's benchmark plan, whichever is more.19, 20 The benchmark plans for Texas and Georgia, for example, exclude weight-loss drugs themselves.21, 22
The weight-loss drugs most lists do include
The standard lists' only weight-loss drugs are phentermine capsules and phendimetrazine tablets, each with prior authorization; Contrave came off the lists on January 1, 2026.1, 23 For phentermine, Centene asks for age 17 or older and a BMI of 30 or more, or 27 or more with a heart risk factor or another weight-related condition such as sleep apnea. At 17, a BMI at or above the 95th percentile for age and sex also counts.24
You also need six months of a diet, exercise and behavior-change program, documented in your records and continuing during treatment, and approvals cover 12 weeks of treatment in all.24 Ask your prescriber how your program will be documented before you pay for one: Georgia's contract, for one, does not pay for weight-loss programs or gym memberships.4
Phentermine's label allows only short-term use, "a few weeks," and does not recommend it for anyone 16 or younger. It rules out a history of cardiovascular disease (such as heart disease, stroke, heart rhythm problems or uncontrolled high blood pressure), an overactive thyroid, glaucoma, agitation, past drug abuse, a past reaction to stimulant-type drugs, pregnancy and breastfeeding. It also rules out MAO inhibitors, such as phenelzine (Nardil), taken in the past 14 days.25, 26
Do not combine it with other weight-loss medicines, and its label also advises against combining it with antidepressants called SSRIs, such as sertraline or fluoxetine. Stop it and see a doctor for new shortness of breath, chest pain, fainting or leg swelling, which can signal a rare lung-artery disease. The label also reports rare heart-valve disease and a risk of abuse, and people with diabetes may need lower insulin or diabetes-pill doses.25
Phendimetrazine's label sets similar limits, adds moderate high blood pressure to them, and links appetite suppressants, phendimetrazine included, to pulmonary hypertension.27 Whether either pill suits you is a question for your own doctor.
Surgery depends on the contract. Arizona's 2026 contract covers bariatric surgery when it is medically necessary for a BMI of 35 or more with an obesity-related condition and failed medical treatment. Georgia's excludes surgical treatment of obesity except as its medical benefits section covers it, and we found no bariatric benefit there.4, 5
Zepbound for sleep apnea, Wegovy for cardiovascular or liver disease
In the 27 standard-list states, Centene's policies leave three narrow routes, each for a diagnosis already in your medical records, not for weight loss. Neither drug is on the standard lists, so your prescriber files a non-formulary exception request, which goes in like a prior authorization.1, 7, 8, 28
All three need at least six months in a physician-directed program like the one above, continuing during treatment. Outside Illinois, people with type 2 diabetes must first have taken three of these four for at least 3 months each: Ozempic or Rybelsus, Trulicity, liraglutide and Mounjaro. The exceptions are clinically significant side effects or a medical reason that rules them out, and for the MASH route Centene says common stomach side effects, such as nausea, do not count. On the heart and sleep apnea routes, people with type 2 diabetes who already take another GLP-1 also need a medical reason to switch, and those side effects do not count there either.7, 8
Zepbound for obstructive sleep apnea. Zepbound is FDA-approved, alongside a reduced-calorie diet and more exercise, to treat moderate to severe obstructive sleep apnea in adults with obesity.17 Centene's criteria include:8
- a sleep study or home sleep test from the past 12 months showing an apnea-hypopnea index (AHI, a count of breathing events per hour of sleep) of 15 or more;
- age 18 or older, a BMI of 30 or more, and no central or mixed sleep apnea;
- symptoms despite using positive airway pressure, such as CPAP, at least 4 hours a night on 70% of nights, or a reason you cannot use it, such as the shape of your airway; and
- the Zepbound KwikPen, which holds four weekly doses, rather than single-dose pens.17
Illinois plans skip the diabetes step, the CPAP rule and the KwikPen rule. The first approval lasts six months. The first renewal needs at least 5% weight loss plus a better sleep measure, such as the AHI, and later renewals last 12 months.8
Wegovy to lower the risk of heart attack and stroke. With the same diet and exercise clause, Wegovy is FDA-approved for adults with established cardiovascular disease and obesity or overweight, to lower their risk of heart attack, stroke and cardiovascular death.16 Centene asks for a past heart attack or stroke, or peripheral artery disease with symptoms; age 18 or older; a BMI of 27 or more; and standard heart care that your prescriber confirms. The first approval lasts six months, the first renewal needs at least 5% weight loss, and later approvals last 12 months.7
Wegovy for MASH. MASH, short for metabolic dysfunction-associated steatohepatitis, is a form of fatty liver disease with inflammation and liver damage that can lead to scarring.29 The Wegovy injection is also approved, with the same clause, for adults with MASH who have moderate to advanced scarring (stage F2 or F3) but not cirrhosis. This is an accelerated approval, so keeping it may depend on a confirmatory trial.16 Centene requires the injection, age 18 or older and a liver or digestive-disease specialist as prescriber or consultant.7
The scarring must show on a liver biopsy from the past 3 years, or on both a blood-test score and an imaging test, such as a liver-stiffness scan, from the past 6 months. Your prescriber must confirm you are treated for related conditions such as diabetes, high cholesterol and high blood pressure. Centene will not approve Wegovy together with Rezdiffra (resmetirom), another MASH medicine.7, 30 The first approval lasts six months; renewals last 12 months and need signs, after at least 12 months of treatment, that the liver disease has improved or not gotten worse.7
From the Zepbound and Wegovy labels:
- Both may harm an unborn baby. Stop Zepbound once you know you are pregnant, and stop Wegovy too if you take it for weight or heart risk; for MASH, its label weighs benefit against risk in pregnancy. Tell your prescriber either way.16, 17
- If you plan to get pregnant, Wegovy's label says to stop it at least 2 months beforehand, because semaglutide stays in the body a long time. If you take it for MASH, make that decision with your prescriber, who weighs the benefit against the risk. Wegovy can also raise your resting heart rate.16
- If you use birth-control pills, pair them with a barrier method, or switch to a non-pill method of birth control, for your first 4 weeks on Zepbound and for 4 weeks after each dose increase.17
For pen sharing, other medicines and the warnings the GLP-1 labels share, see the warnings section below.
California and New York do it differently
California. Ambetter from Health Net's 2026 drug list, updated October 1, 2026, says: "Most plans do cover weight loss medications after prior authorization has been approved." It names Wegovy (pen and tablets), Zepbound, Foundayo, Saxenda, Contrave, Qsymia, orlistat and phentermine.11 Health Net's Wegovy and Zepbound policies, last reviewed in March and July 2026, add two routes that Centene's policies lack:31, 32
-
Adults, for weight loss: a BMI of 40 or more on Marketplace plans and, with type 2 diabetes, 3 months on each of Ozempic or Rybelsus, Trulicity, liraglutide and Mounjaro first.31, 32 The first renewal needs at least 5% weight loss.
-
Teens 12 to 17: of these two drugs, only the Wegovy injection, for teens without type 2 diabetes whose BMI is at or above the 95th percentile for age and sex. The first renewal needs a 5% drop in BMI. Zepbound and the Wegovy pill start at 18.
For heart risk, MASH and sleep apnea, Health Net's tests match Centene's above, including the rules on stomach side effects, and the switching rule also covers Health Net's weight-loss route. The differences: with type 2 diabetes, you need 3 months on each of all four diabetes drugs first, not three of them (the heart route lists three, leaving out Mounjaro). On the heart, MASH and sleep apnea routes, first approvals last up to 16 weeks (six months for MASH) and renewals six months; on the weight-loss route, approvals and renewals last up to 16 weeks.31, 32
Every route needs six months in a weight-loss program first, such as Weight Watchers or Active&Fit, which Health Net names, or a lifestyle plan from your prescriber, and you stay in it. A request for Zepbound's single-dose pens must use the KwikPen instead. If you started on a compounded drug, samples or self-pay supply from NovoCare or LillyDirect, Health Net treats your request as a new start and applies the starting criteria.31, 32
Health Net notes that some PPO plans may not cover weight-loss drugs and that compounded medications and samples are excluded.31, 32 The two 2026 contracts we read, an HMO and a PPO, cover obesity drugs when medically necessary for morbid obesity or when you meet Health Net's prior authorization rules. The 2027 list keeps the same weight-loss section.33, 34, 35
New York. Fidelis Care's 2026 Ambetter list includes Ozempic, Contrave, phentermine and phentermine-topiramate, all with prior authorization, but not Mounjaro, Wegovy, Zepbound or Foundayo. Its 2027 list adds Mounjaro and still leaves out the other three.10, 36
The 2026 Silver plan contract we read allows a formulary exception request for an unlisted drug, with an external appeal if it is refused, and we found no weight-loss drug exclusion in it.12 Fidelis Care's list says such requests are reviewed against drug-specific prior authorization criteria or its standard criteria for unlisted drugs.10 Centene's exception policy, which has rules for New York requests too, treats non-formulary weight-loss drugs as an excluded use.18 We found nothing showing whether Fidelis Care applies it to Wegovy, Zepbound or Foundayo.
Label points for the drugs only these two lists add:
Foundayo may harm an unborn baby: its label calls for effective birth control during treatment and stopping it once you know you are pregnant. If you use birth-control pills, add a barrier method or switch to a non-pill method of birth control for 30 days after starting Foundayo and after each dose increase. It is not recommended while breastfeeding or with severe liver impairment. Its label also says to avoid some medicines that strongly block or speed up a liver enzyme called CYP3A4 (ritonavir is its example), and it caps simvastatin at 20 mg a day.2
Saxenda, liraglutide for weight loss, may also harm an unborn baby, so it is stopped once a pregnancy is known, and it can raise your resting heart rate.37 Qsymia, the brand of phentermine-topiramate, can harm an unborn baby too. Its label recommends a pregnancy test before starting and every month for anyone who can become pregnant, plus effective birth control. It also rules Qsymia out with glaucoma, an overactive thyroid or an MAO inhibitor taken in the past 14 days.38
Contrave carries a boxed warning about suicidal thoughts and behaviors. It is not for people with uncontrolled high blood pressure, seizures, bulimia or anorexia, other bupropion products, long-term opioid use or an MAO inhibitor in the past 14 days. Nor is it for anyone suddenly stopping alcohol, benzodiazepines, barbiturates or seizure medicines.39 NIDDK says not to take orlistat if you have trouble absorbing nutrients from food or have cholestasis (blocked bile flow), and advises never taking any weight-management medicine during pregnancy or while planning one.40
Ozempic and Mounjaro for type 2 diabetes
FDA approved Ozempic (for adults) and Mounjaro (for adults and children from age 10) to improve blood sugar in type 2 diabetes, alongside diet and exercise. In adults with type 2 diabetes, both are also approved to lower the risk of heart attack, stroke and cardiovascular death: Ozempic for people with established cardiovascular disease, Mounjaro for people at high risk of those events. Ozempic is also approved to lower the risk of lasting loss of kidney function, kidney failure and cardiovascular death in people who also have chronic kidney disease. Rybelsus, Trulicity and Victoza have heart-risk approvals too.41, 42, 43, 44, 45
Neither Ozempic nor Mounjaro is approved for weight loss. Ozempic and Wegovy are both semaglutide, and Mounjaro and Zepbound are both tirzepatide, but each brand has its own approved uses, and Centene's coverage rules follow the brand.7, 8, 9, 16, 17, 41, 42
Centene's policy for these drugs, last reviewed in September 2026, approves Ozempic, Rybelsus, Trulicity, Mounjaro, liraglutide and a few others when your prescriber sends records, such as chart notes or lab results, showing that:9
- you have a diagnosis of type 2 diabetes;
- you are not taking another drug of this type at the same time; and
- the dose stays within FDA's maximum.
Approvals last 12 months. Mounjaro joined this preferred group, which needs no trial of other diabetes medicines first, in the September 2026 revision. Each Ambetter plan sets the date that change takes effect, so ask yours whether it applies yet.9
Prediabetes is not the type 2 diabetes diagnosis the policy asks for, and neither prediabetes nor weight loss is an FDA-approved use of Ozempic or Mounjaro. The policy lists uses FDA has not approved under coverage that is "NOT authorized," unless Centene's separate off-label rules are met.9, 41, 42 The "Ozempic tabs" on the lists are a type 2 diabetes pill that shares Rybelsus's label; Centene says the name comes from the maker's rebranding of a newer Rybelsus tablet.9, 43
From these diabetes drugs' labels:
- The Ozempic (pen and tablet), Rybelsus, Mounjaro, Trulicity and Victoza (liraglutide) labels warn, based on animal studies, that the drug may harm an unborn baby. They leave use in pregnancy to a weighing of benefit against risk, so tell your prescriber if you become pregnant or plan to. The Ozempic and Rybelsus labels advise stopping 2 months or more before a planned pregnancy; ask what to use for your diabetes meanwhile.41, 42, 43, 44, 45
- With Mounjaro, birth-control pills may work less well: pair them with a barrier method, or switch to a non-pill method of birth control, for the first 4 weeks and for 4 weeks after each dose increase.42
What you would pay. Both drugs sit on tier 2. Whether a drug is subject to your deductible depends on its tier, and your Schedule of Benefits shows your cost share; we did not check individual plans' amounts.1, 4, 28
If your plan covers Ozempic or Mounjaro for your diabetes, each maker's savings card can lower your share to as little as $25 a fill, up to a savings cap.46, 47 As of October 3, 2026, Novo Nordisk's terms say Marketplace plans such as Ambetter are not government programs for its Ozempic offer.46 Lilly's Mounjaro card ends December 31, 2026, and its terms exclude government programs without mentioning Marketplace plans, so ask Lilly before you count on it.47 Our guide to GLP-1 costs explains who can use which drugmaker offer.
Three documents that settle it for your plan
Your own plan's answer is in these three documents:
-
Your state's drug list, for the right year. For most states, Ambetter posts the lists on the state's pharmacy page; Georgia's carries the 2027, 2026 and 2025 lists and a list of 2026 changes. California members use Health Net's list, and New York members use the one Fidelis Care posts on its own site. Search your plan year's list for the drug's name.1, 10, 11, 28
-
Your Evidence of Coverage. With your Schedule of Benefits, this is your contract. Check the exclusions in its prescription drug section; Georgia's heads them "Non-Covered Services and Exclusions," and the weight-loss drug rule is there.4
-
Your Schedule of Benefits. It lists what you pay for each type of covered service.4
Your Ambetter online member account shows your plan benefits and ID card, and your contract prints your plan's Member Services number on its pages.4, 48
How a request is filed. Your prescriber or pharmacist sends a prior authorization to Centene Pharmacy Services, on Ambetter's form or through CoverMyMeds, and a licensed clinical pharmacist checks it against Ambetter's criteria. A request for a drug that is not on the list goes in the same way.28 For those requests, Ambetter's contract and the federal rule require a decision within 72 hours of receipt, or 24 hours if waiting could seriously harm your health or you are already being treated with the drug.4, 20
Picking a plan for 2027. HealthCare.gov shows each plan's covered drugs and lets you search for your prescriptions while you compare.49 On HealthCare.gov, Open Enrollment for 2027 coverage starts November 1, 2026; December 15 is the last day to pick a plan that starts January 1, and enrollment ends January 15.50 How you apply depends on whether your state has its own Marketplace, and HealthCare.gov's state page shows how to apply in yours.51
A richer metal level will not add Wegovy, Zepbound or Foundayo in the 27 standard-list states. None of their 2026 lists, or the 2027 lists posted so far, includes them, and Texas's 2026 list, for one, applies to every bronze, silver and gold plan there.1, 13, 52
Asking Ambetter to reconsider
When Ambetter turns down a request, it must tell you in writing and explain why; for a drug that is not on the list, the notice must give the specific reasons or name the missing information.1, 53 Whatever the reason, even an exclusion, you or someone you name, such as your prescriber, can file an internal appeal within 180 days.4, 53 Georgia's 2026 contract, for example, decides an appeal for a drug that is not on its drug list, such as Zepbound, within 72 hours of receipt. The plan can take up to 14 more days if it needs more information.4
If the appeal fails, you have 4 months to ask for an external review by an independent reviewer, though a refusal based only on a contract exclusion may not qualify.4, 54 Use the deadlines and addresses on your own notice, and see our prior authorization guide for the steps, what to send and where to get free help.
What a request or appeal can still do, by situation:
-
Ozempic, Mounjaro or another listed diabetes drug. If the notice says the diagnosis or another criterion was not shown, your prescriber can send the missing records; the appeal considers everything you submit.4, 9
-
Zepbound for sleep apnea, or Wegovy for cardiovascular disease or MASH. These are exception requests, so besides appealing, you or your prescriber can have an independent review organization look at a refusal, a step federal rules and Ambetter's contracts require.4, 20 An old sleep test, missing CPAP records or no specialist on a MASH request are gaps your prescriber may be able to fill.7, 8
-
Wegovy, Zepbound or Foundayo for weight loss in the 27 standard-list states. You can still ask for an exception, appeal a refusal and use that independent review. Centene's written rules say weight-loss use will not be approved, so a request has a real chance mainly if you have one of the diagnoses above and it was coded as weight loss.4, 18, 20
-
New York or California. Fidelis Care's contract gives the exception process with an external appeal, and Health Net judges California requests by its own criteria.12, 31, 32
Warnings shared by the nine GLP-1 drugs on this page
This page names nine GLP-1 drugs: Ozempic (pens and tablets), Rybelsus, Mounjaro, Trulicity and liraglutide on the standard lists, plus Saxenda, Wegovy, Zepbound and Foundayo on California's. Whichever one a plan approves, or you buy yourself, these warnings come with it.
Each of the nine labels opens with a boxed warning on thyroid C-cell tumors, which all but Foundayo caused in rodent studies. Nobody knows whether any of these drugs causes such tumors, including a thyroid cancer called medullary thyroid carcinoma (MTC), in people. Orforglipron, the drug in Foundayo, does not act on the GLP-1 receptor in rats or mice, so those studies could not show whether it causes these tumors. It does act on the human receptor, and Foundayo carries the same boxed warning and MTC rule.2, 16, 17, 37, 41, 42, 43, 44, 45
If you or anyone in your family has had MTC, or you have multiple endocrine neoplasia syndrome type 2 (MEN 2), none of the nine is for you. The same goes after a serious allergic reaction to the drug or anything in it, and none is recommended with severe gastroparesis (very slow stomach emptying). All nine warn of pancreatitis, including fatal cases, gallbladder disease, severe stomach and bowel reactions, and kidney injury from losing fluids, sometimes needing dialysis. Rarely, food or liquid has entered the lungs during anesthesia or deep sedation, so tell every doctor and dentist you take one before a planned procedure.2, 16, 17, 37, 41, 42, 43, 44, 45
Low blood sugar is most likely with insulin or a sulfonylurea (a type of diabetes pill), and the Zepbound, Foundayo and Wegovy labels report it in adults without type 2 diabetes too, as Saxenda's does in teens.2, 16, 17, 37, 41, 42, 43, 44, 45 If you have type 2 diabetes, the Ozempic (pen and tablet), Rybelsus, Mounjaro, Trulicity, Wegovy, Zepbound and Foundayo labels warn that diabetic eye disease (retinopathy) can get worse, especially if you already have it. Tell your prescriber if you have it.2, 16, 17, 41, 42, 43, 44 Centene will not approve two GLP-1 drugs at once, and the Wegovy, Zepbound and Foundayo labels advise against adding any other GLP-1, compounded semaglutide or tirzepatide included.2, 7, 8, 9, 16, 17
All nine labels warn that the drug may harm an unborn baby; for the five diabetes drugs, the labels base that warning on animal studies. When to stop, and what to do about birth-control pills, differs by drug: see the points for Zepbound and Wegovy, Foundayo and Saxenda and the diabetes drugs.2, 16, 17, 37, 41, 42, 43, 44, 45
Because these drugs slow how fast your stomach empties, they can change how well pills you take by mouth are absorbed; the Zepbound and Mounjaro labels single out warfarin, a blood thinner.2, 16, 17, 37, 41, 42, 43, 44, 45 Semaglutide tablets (the Wegovy pill, Ozempic tablets and Rybelsus) go down on an empty stomach with no more than 4 ounces of water, then nothing else by mouth for 30 minutes. They increased levothyroxine (thyroid hormone) exposure by 33% in a study, and breastfeeding is not recommended while you take them.16, 43
Ozempic, Victoza and Saxenda pens, Mounjaro and Zepbound KwikPens and Wegovy FlexTouch pens are for one person only, even with a fresh needle, because sharing can pass on blood-borne infections.16, 17, 37, 41, 42, 45 Under 18, only Mounjaro, Trulicity and liraglutide (type 2 diabetes, from age 10) and the Wegovy injection and Saxenda (obesity, from age 12; Saxenda above 60 kg) carry a label use; the rest are for adults.2, 16, 17, 37, 41, 42, 43, 44, 45
Signs to act on, from the Medication Guides:17, 41
-
Belly pain. Severe stomach pain that will not go away, with or without vomiting, sometimes felt in your back, can mean pancreatitis: stop the medicine and call your prescriber right away. Upper stomach pain with fever, yellowing skin or eyes, or clay-colored stools can mean a gallbladder problem: tell your prescriber right away.
-
Vomiting, nausea or diarrhea that keeps going. Call your prescriber right away and keep drinking fluids, because dehydration can hurt your kidneys.
-
Swelling or trouble breathing. A swollen face, lips, tongue or throat, trouble breathing or swallowing, fainting or dizziness, a racing heart, or a severe rash or itching can mean a serious allergic reaction: stop the medicine and get medical help right away.
-
Shakiness, sweating, dizziness or confusion. These can mean low blood sugar; ask before your first dose how to recognize and treat it.
-
Eyesight or neck changes. With type 2 diabetes, report any vision change. Anyone should report a neck lump or swelling, hoarseness, trouble swallowing or shortness of breath, possible signs of a thyroid tumor.
-
Too much medicine. If you take too much, call Poison Help (1-800-222-1222) or your prescriber, or go to an emergency room right away.
These are not all the risks; each prescription's Medication Guide lists more.17
Paying out of pocket instead
If Ambetter will not pay, Novo Nordisk sells Wegovy to cash buyers through NovoCare Pharmacy, and Lilly sells Zepbound through LillyDirect.55, 56 Have your prescriber send the prescription to NovoCare Pharmacy or LillyDirect Pharmacy. Both makers attach eligibility rules to these prices; Lilly's Zepbound KwikPen self-pay price, for one, needs a prescription for a use the label approves.56, 57, 58 NovoCare notes that money spent outside your insurance does not count toward your deductible or out-of-pocket limit.55
Our guide to GLP-1 costs without insurance lists each maker's price by dose with its conditions, and our Foundayo cost page covers Foundayo.
Before you pay for Wegovy, Zepbound or Foundayo, check its pregnancy rules: all three labels say the drug may harm an unborn baby. Wegovy's label says to stop it at least 2 months before you try to get pregnant. Zepbound and Foundayo can make birth-control pills work less well for a few weeks after you start and after each dose increase. Each drug's details are with Zepbound and Wegovy and Foundayo.2, 16, 17
Compounded drugs, FDA's test and PlexusDx
FDA has not approved compounded semaglutide or tirzepatide, and it does not review them for safety, effectiveness or quality before they are sold. Some reports it has received, including cases that needed hospital care, may be related to dosing mistakes with compounded semaglutide injections. Others, some of them serious, may be related to prescriptions of compounded semaglutide or tirzepatide at doses beyond the approved labels. FDA also says many side effects reported with compounded products resemble the approved drugs' and are likely underreported, so go through the warnings above, pregnancy included, with any prescriber.59
FDA says compounded drugs should be used only when an FDA-approved drug cannot meet a patient's medical needs. Its guidance adds that a lower price is not enough reason to copy an approved drug.59, 60 Ambetter's exclusion is a payment decision, not a medical need, so by FDA's standard it is not a reason to use a compounded drug. See how compounding is regulated and how to check a compounded provider.
If you are an adult who has neither obesity nor overweight with a weight-related health problem, using Wegovy, Zepbound or Foundayo to lose weight would be off-label. Ozempic and Mounjaro are not approved for weight loss for anyone, and compounded semaglutide and tirzepatide are not FDA-approved for any use.2, 16, 17, 41, 42, 59
Start with your own doctor, who knows your history and can tell whether one of the Ambetter routes above fits you. That conversation should come before any online program, and PlexusDx runs one, so the advice applies to us too. Our page on GLP-1s without obesity or overweight sets out the options at lower weights.
PlexusDx, which publishes this page, offers compounded GLP-1 programs. As of October 19, 2026:
-
FDA's test applies here too. Lone Star Virtual Health's answer is that no blanket reason exists. Its physicians record why the formulation fits each patient better than an FDA-approved choice such as Wegovy, Zepbound or Foundayo, explain that to the patient with the reminder that compounded drugs lack FDA approval, and rely on added B12, B6 or glycine only as far as the patient's clinical needs support it.
-
Who prescribes. U.S.-licensed clinicians from Lone Star Virtual Health, the company that provides PlexusDx's prescribing clinicians, make the medical decisions, including whether to prescribe. PlexusDx does not practice medicine.
-
Who the programs are for. Adults 18 and older. Lone Star's physicians decide using one set of thresholds across PlexusDx's semaglutide, tirzepatide and Microdose GLP-1 plans: a BMI of 25 for a newcomer and 22 for someone already on, or recently off, a GLP-1 (within two months). For a new patient under the labels' line, 30, or 27 alongside a weight-related condition, that would mean off-label treatment. Pregnancy, pancreatitis, gastroparesis and thyroid cancer are among the intake's questions; eye damage from diabetes (diabetic retinopathy), surgery you have coming up and allergy to B12 or glycine are not. In some states, Lone Star's policy calls for a live first visit before it prescribes; our provider guide names them.
-
Pharmacies. Prescriptions are filled by state-licensed 503A compounding pharmacies; a patient can request a particular one, subject to availability and the law. FDA notes that federal law does not require pharmacies of this kind to report side effects to it.59 Formulations and added ingredients can vary by pharmacy and fill, so if you have allergies, ask what your prescription contains.
-
Payment. Your Ambetter plan pays nothing toward these programs: they are self-pay, and PlexusDx does not bill any insurer (see PlexusDx's Terms of Service). Like other purchases your plan does not cover, what you pay does not count toward your deductible or out-of-pocket maximum; Georgia's contract, for one, counts only cost sharing for covered services.4 PlexusDx accepts eligible HSA and FSA payment methods and can provide itemized documentation. Whether your account covers the cost is up to its plan administrator and tax law (see our HSA and FSA guide).
-
Prices and policies. Plan prices and terms are in our guide to GLP-1 costs without insurance, and PlexusDx's Refund & Cancellation Policy sets out its cancellation, pause and refund rules.
-
Brand-name drugs. PlexusDx does not sell or ship brand-name medications. If you would prefer a brand-name, FDA-approved medication, your provider may write a prescription you can fill at the pharmacy of your choice. Ambetter's drug lists, contracts and criteria still decide whether your plan pays for it.
Start with your Ambetter plan if you live in California or New York, or if you have type 2 diabetes, sleep apnea confirmed by a sleep test, established cardiovascular disease, or MASH with moderate to advanced liver scarring. Ask your own doctor, or the clinician who treats that condition, to file the request.
Sources
-
2026 Formulary (Georgia; example of the 29 lists for the 27 standard-list states), Ambetter from Peach State Health Plan, accessed October 3, 2026.
-
FOUNDAYO (orforglipron) tablets: prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
Health Insurance Marketplace Plans from Ambetter Health, Centene Corporation, accessed October 3, 2026.
-
Ambetter Plus Select 2026 Evidence of Coverage, plan 70893GA007 (Georgia; example of the standard contracts), Ambetter from Peach State Health Plan, accessed October 3, 2026.
-
2026 Evidence of Coverage, plan 12613AZ001 (Arizona), Ambetter Health Solutions, issued by Health Net Community Solutions of Arizona, Inc., accessed October 3, 2026.
-
Individual Health Benefits Plan A/50, 2026 (New Jersey), Ambetter from WellCare of New Jersey, accessed October 3, 2026.
-
Clinical Policy: Semaglutide (Wegovy), CP.PMN.295 (last review 09.26), Centene Corporation, posted by Ambetter, accessed October 3, 2026.
-
Clinical Policy: Tirzepatide (Zepbound), CP.PMN.298 (last review 09.26), Centene Corporation, posted by Ambetter, accessed October 3, 2026.
-
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, HIM.PA.53 (last review 09.26), Centene Corporation, posted by Ambetter, accessed October 3, 2026.
-
Ambetter from Fidelis Care Qualified Health Plans (Individual and Family Plan) Formulary, 2026, Fidelis Care, accessed October 3, 2026.
-
California Ambetter from Health Net Drug List for Individual & Family Plans, 2026 (updated October 1, 2026), Health Net of California, accessed October 3, 2026.
-
Health Maintenance Organization Contract, Silver plan (2026), Ambetter from Fidelis Care, accessed October 3, 2026.
-
2027 Formulary (Georgia; example of the 26 lists posted for 25 states), Ambetter from Peach State Health Plan, accessed October 3, 2026.
-
New Hampshire Pharmacy Coverage, Ambetter from NH Healthy Families, accessed October 3, 2026.
-
Prescription Drug Coverage in Delaware, Ambetter Health, accessed October 3, 2026.
-
WEGOVY (semaglutide) injection and tablets: prescribing information and Medication Guide, Novo Nordisk, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
ZEPBOUND (tirzepatide): prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
Clinical Policy: Brand Name Override and Non-Formulary Medications, HIM.PA.103 (last review 11.25), Centene Corporation, posted by Ambetter, accessed October 3, 2026.
-
Information on Essential Health Benefits (EHB) Benchmark Plans, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
-
45 CFR 156.122, Prescription drug benefits, Electronic Code of Federal Regulations, accessed October 3, 2026.
-
Texas EHB Benchmark Plan (2025-2027) documents, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
-
Georgia EHB Benchmark Plan (2025-2027) documents, Centers for Medicare & Medicaid Services, accessed October 3, 2026.
-
2026 Formulary Changes (Georgia), Ambetter from Peach State Health Plan, accessed October 3, 2026.
-
Clinical Policy: Phentermine (Adipex-P, Lomaira), CP.PCH.13 (last review 05.26), Centene Corporation, posted by Ambetter, accessed October 3, 2026.
-
Phentermine hydrochloride capsules: prescribing information, Preferred Pharmaceuticals, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
Phentermine: MedlinePlus Drug Information, MedlinePlus (National Library of Medicine), accessed October 3, 2026.
-
Phendimetrazine tartrate tablets: prescribing information, Preferred Pharmaceuticals, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
Georgia Pharmacy Coverage, Ambetter from Peach State Health Plan, accessed October 3, 2026.
-
Definition & Facts of NAFLD & NASH, National Institute of Diabetes and Digestive and Kidney Diseases (NIH), accessed October 3, 2026.
-
REZDIFFRA (resmetirom) tablets: prescribing information, Madrigal Pharmaceuticals, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
Clinical Policy: Semaglutide (Wegovy), HNCA.CP.CPA.352 (last review 03.26), Health Net of California, accessed October 3, 2026.
-
Clinical Policy: Tirzepatide (Zepbound), HNCA.CP.CPA.359 (last review 07.26), Health Net of California, accessed October 3, 2026.
-
Platinum 90 Ambetter HMO Plus, 2026 Plan Contract and Evidence of Coverage, Health Net of California, accessed October 3, 2026.
-
Minimum Coverage Ambetter PPO, 2026 Plan Contract and Evidence of Coverage, Health Net of California, accessed October 3, 2026.
-
California Ambetter from Health Net Drug List for Individual & Family Plans, 2027 (updated January 1, 2027), Health Net of California, accessed October 3, 2026.
-
Ambetter from Fidelis Care Qualified Health Plans (Individual and Family Plan) Formulary, 2027, Fidelis Care, accessed October 3, 2026.
-
SAXENDA (liraglutide) injection: prescribing information and Medication Guide, Novo Nordisk, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
QSYMIA (phentermine and topiramate extended-release) capsules: prescribing information, Vivus, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets: prescribing information, Nalpropion Pharmaceuticals, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
Prescription Medications to Treat Overweight & Obesity, National Institute of Diabetes and Digestive and Kidney Diseases (NIH), accessed October 3, 2026.
-
OZEMPIC (semaglutide) injection: prescribing information and Medication Guide, Novo Nordisk, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
MOUNJARO (tirzepatide): prescribing information and Medication Guide, Eli Lilly and Company, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information, Novo Nordisk, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
TRULICITY (dulaglutide) injection: prescribing information, Eli Lilly and Company, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
VICTOZA (liraglutide) injection: prescribing information, Novo Nordisk, via DailyMed (National Library of Medicine), accessed October 3, 2026.
-
Diabetes Savings Card Program (Ozempic and Rybelsus savings offer terms), Novo Nordisk (NovoCare), accessed October 3, 2026.
-
Savings & Coverage, Mounjaro (tirzepatide), Eli Lilly and Company, accessed October 3, 2026.
-
Handbooks and Forms for Members, Ambetter from Peach State Health Plan, accessed October 3, 2026.
-
3 things to know before you pick a health insurance plan, HealthCare.gov, accessed October 3, 2026.
-
When can you get health insurance?, HealthCare.gov, accessed October 3, 2026.
-
The Marketplace in your state, HealthCare.gov, accessed October 3, 2026.
-
2026 Formulary (Texas), Ambetter from Superior HealthPlan, accessed October 3, 2026.
-
Internal appeals, HealthCare.gov, accessed October 3, 2026.
-
External Review, HealthCare.gov, accessed October 3, 2026.
-
Wegovy (semaglutide) Cost, Coverage, & Savings Resources, Novo Nordisk (NovoCare), accessed October 3, 2026.
-
Authentic Zepbound (tirzepatide) Shipped to You, Eli Lilly and Company (LillyDirect), accessed October 3, 2026.
-
Get Your GLP-1 Medications Delivered with NovoCare Pharmacy, Novo Nordisk (NovoCare), accessed October 3, 2026.
-
Zepbound (tirzepatide): Full Terms and Conditions, Eli Lilly and Company, accessed October 3, 2026.
-
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration, accessed October 3, 2026.
-
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act (guidance, January 2018), U.S. Food and Drug Administration, accessed October 3, 2026.
How we made this page
Ambetter's answer sits in different documents for each state and each year. On October 3, 2026, AI tools downloaded and searched the 2026 drug lists for all 29 Ambetter states (31 files), the 2027 lists then posted for 27 of the 29 states (all but New Hampshire and Delaware), a 2026 Evidence of Coverage for each of the 27 states on Centene's standard list plus three California and New York contracts, and Centene's and Health Net's coverage policies. A script searched every list for every drug name, Foundayo and Contrave included, and every contract for its weight-loss wording. Where many states share the same text, the sources list cites Georgia's document as the example.
The AI tools also read the HealthCare.gov and CMS pages and the federal rule on Marketplace drug lists and appeals, 14 FDA drug labels, FDA's pages on compounded drugs, two NIH pages (on weight-management medicines and on MASH), MedlinePlus's phentermine page, Novo Nordisk's and Lilly's offer terms and pharmacy pages, and Ambetter's member pages, then drafted the text and the table from those sources. The PlexusDx list near the end is the exception: it describes our own programs as of October 19, 2026, from our records and website rather than the sources listed, so its statements about PlexusDx carry no source number.
Before review, a script confirmed that every quotation in our evidence file appears in the text of the list, contract, policy or label it came from, and AI reviewers then read the page claim by claim against those documents. Those checks show what Ambetter's documents say; they are not a clinician weighing your health or a lawyer reading your contract, and they do not tell you how Ambetter will decide your request. The AI tools read at least one contract per state, not every plan's, and could not see members' Schedules of Benefits or any approval figures, so the page points you to your own documents for those.
An earlier PlexusDx post at this address said Ambetter plans may cover Ozempic for weight loss, gave approval criteria that are not Ambetter's, presented compounded drugs as a way around prior authorization and promoted PlexusDx prices. None of its text, approval criteria or prices was kept. Ambetter, Centene, Health Net, Fidelis Care, CoverMyMeds and the drug and program names on this page belong to their owners; we use them only to say whose plans, documents and products we mean, and none of these companies reviewed or endorsed this page.
Jay Hastings reviewed and approved this version on October 19, 2026. Dr. Asad K. Niazi, MD, MPH, reviewed the medical content on October 17, 2026. He is co-founder and CEO of Lone Star Virtual Health, the company that provides PlexusDx's prescribing clinicians, so he has a business relationship with PlexusDx. PlexusDx sells compounded GLP-1 treatment, so we have a financial interest in this topic. Ambetter's lists and contracts change, and this page reflects them as of October 3, 2026; our editorial policy applies to it.
Share:
GLP-1 Medicines After a Thyroidectomy: It Depends on Why It Was Removed
Tirzepatide Weight Loss in Studies, From the First Month to 3 Years